培塞利珠单抗治疗免疫介导炎症性疾病所致葡萄膜炎的长期随访:80例患者的多中心研究
多中心研究纳入80例(111只患眼)对传统免疫抑制剂难治的免疫介导炎症性疾病相关葡萄膜炎患者,评估培塞利珠单抗的有效性与安全性。结果显示培塞利珠单抗似乎有效且安全,即使对既往生物制剂难治的患者亦然。
要点
- 培塞利珠单抗在多种免疫介导炎症性疾病相关葡萄膜炎中似乎有效且安全。
- 研究纳入80例患者共111只患眼,平均年龄41.6±11.7岁。
- 即使对既往生物制剂难治的患者,培塞利珠单抗似乎仍有效。
核心结论
- 培塞利珠单抗在多种免疫介导炎症性疾病相关葡萄膜炎中似乎有效且安全,即使对既往生物制剂难治的患者亦然。
研究设计与样本
- 多中心研究纳入80例(33例男性/47例女性)接受培塞利珠单抗治疗、对传统免疫抑制剂难治的免疫介导炎症性疾病相关葡萄膜炎患者,共111只患眼,平均年龄41.6±11.7岁。
主要发现
- 免疫介导炎症性疾病包括脊柱关节炎43例、白塞病10例、银屑病关节炎8例、克罗恩病4例、结节病2例、幼年特发性关节炎1例、反应性关节炎1例、类风湿关节炎1例、复发性多软骨炎1例。
- 有效性通过最佳矫正视力、前房细胞、玻璃体炎、黄斑厚度和视网膜血管炎等眼部参数评估,并与基线及第1周、第1、3、6个月、第1年和第2年比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). METHODS: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. RESULTS: We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
引用
- Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022. PMID: 36597972. doi:10.1136/rmdopen-2022-002693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。